Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
about
Chimeric Antigen Receptors Modified T-Cells for Cancer TherapyFine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and functionNKG2D ligands as therapeutic targetsBispecific T-cell engagers for cancer immunotherapy.M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancerChitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice.NKG2D CARs as cell therapy for cancer.Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapyPrognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas.Genetics, genomics, and evolutionary biology of NKG2D ligands.Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles.NK cells: immune cross-talk and therapeutic implications.B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityOrchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma.Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells.Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.Hunting for clinical translation with innate-like immune cells and their receptors.γδ T cells as a potential tool in colon cancer immunotherapy.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance.Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution.A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma.Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy
P2860
Q26773309-CA2DBAE2-FAFE-4F72-B193-69369F59E597Q26830239-301F3383-DB04-4108-B5DA-76DA7F47A82AQ27014888-630D937E-4053-40FC-9B2D-86BB9454F3B8Q27693313-908E5DC6-3FA3-43F5-A41E-C565D76B4653Q30465410-1D61832D-5AF2-4AED-A3EF-9F38674C30D3Q33589381-91A1ECA0-AAED-4CCB-AAA6-716013E7EC35Q33595873-EBC6A50D-F8DB-42BC-866B-A46DF0016DA0Q34076429-87B8AE4E-ADC4-4F3D-BCC2-1DB117DF10B8Q34255022-35A8ABDD-DCA1-4A5E-85E1-388E51E3AA50Q34489980-AD6370BD-D2AC-4E95-B750-5DA344EA2E4EQ35168522-E0B8BAAE-67C1-4F8D-929D-1C482097E08FQ35591444-77CC92F8-5C6C-4791-8ADA-C66F0F2F1E7CQ35613233-0C16A018-A80C-426C-AAB1-3FEB51BB74B4Q35783394-CC8CA61A-BE70-4B1E-B15F-655110C51379Q35871726-B796DF08-2D7D-4200-B14E-ACDE40332DAFQ36082118-F1BC69AD-3D76-4FF2-B50B-3DEAD225103EQ36757142-038583B7-E853-4C4C-B6A8-E76512F32F8AQ37077413-63D6190C-B997-46FC-B107-B02FB993C217Q37622429-95D08803-9967-4963-866B-FB340F0C5AB5Q37714514-FDFC26CD-011D-4D86-9381-24BDF2B1B88AQ37714638-96CBD9F3-47C7-4D25-9BC3-51F789828B70Q38171917-DD30053F-7F80-4590-8553-1EAF23A2B901Q38262257-EC092546-88E2-4716-8942-FAAC1DA1B420Q38730881-F584BE1B-DCAF-4859-AF82-B6B72CD6E5F1Q38849985-7D3936A9-7023-4F0E-968B-69A46DEA49BAQ39203569-BBF9A139-9DF8-4B11-B875-092CFE4FC606Q46652322-5D4F3A4A-0065-4334-B2A8-FD2ED0481308Q47216941-53590641-431E-411D-8928-5C8C29620149Q47433391-FD3C5B92-D299-4CA9-ACB1-46FEBE98B817Q54978920-02B185F2-4457-4F18-9FCF-A01042FC33A9Q55311835-13471BBB-39D5-4FA5-802C-09B365F8B972Q58750637-80168258-A146-4711-9361-5B4D3047B194
P2860
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@ast
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@en
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@nl
type
label
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@ast
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@en
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@nl
prefLabel
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@ast
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@en
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@nl
P2860
P1433
P1476
Cancer immunotherapy using a b ...... both T cells and tumor cells.
@en
P2093
Charles L Sentman
Tong Zhang
P2860
P304
P356
10.1158/0008-5472.CAN-10-3200
P407
P577
2011-01-31T00:00:00Z